221 related articles for article (PubMed ID: 30565132)
1. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
Cao X; Zhao B
Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
[TBL] [Abstract][Full Text] [Related]
2. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
3. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
4. Heat stress activates YAP/TAZ to induce the heat shock transcriptome.
Luo M; Meng Z; Moroishi T; Lin KC; Shen G; Mo F; Shao B; Wei X; Zhang P; Wei Y; Guan KL
Nat Cell Biol; 2020 Dec; 22(12):1447-1459. PubMed ID: 33199845
[TBL] [Abstract][Full Text] [Related]
5. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Mediated Approaches to Regulate YAP/TAZ Levels.
Quinton RJ; Ganem NJ
Methods Mol Biol; 2019; 1893():203-214. PubMed ID: 30565136
[TBL] [Abstract][Full Text] [Related]
7. Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.
Ning B; Tilston-Lunel AM; Simonetti J; Hicks-Berthet J; Matschulat A; Pfefferkorn R; Spira A; Edwards M; Mazzilli S; Lenburg ME; Beane JE; Varelas X
J Exp Clin Cancer Res; 2023 May; 42(1):116. PubMed ID: 37150829
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.
Zanconato F; Forcato M; Battilana G; Azzolin L; Quaranta E; Bodega B; Rosato A; Bicciato S; Cordenonsi M; Piccolo S
Nat Cell Biol; 2015 Sep; 17(9):1218-27. PubMed ID: 26258633
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.
Yu FX; Zhao B; Panupinthu N; Jewell JL; Lian I; Wang LH; Zhao J; Yuan H; Tumaneng K; Li H; Fu XD; Mills GB; Guan KL
Cell; 2012 Aug; 150(4):780-91. PubMed ID: 22863277
[TBL] [Abstract][Full Text] [Related]
10. TAZ facilitates breast tumor growth by promoting an immune-suppressive tumor microenvironment.
Gershoni A; Hassin O; Nataraj NB; Baruch S; Avioz-Seligman A; Pirona AC; Fellus-Alyagor L; Meir Salame T; Mukherjee S; Mallel G; Yarden Y; Aylon Y; Oren M
Mol Oncol; 2023 Dec; 17(12):2675-2693. PubMed ID: 37716913
[TBL] [Abstract][Full Text] [Related]
11. AR activates YAP/TAZ differentially in prostate cancer.
Salem O; Jia S; Qian BZ; Hansen CG
Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37385752
[TBL] [Abstract][Full Text] [Related]
12. Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression.
Lu Y; Wu T; Gutman O; Lu H; Zhou Q; Henis YI; Luo K
Nat Cell Biol; 2020 Apr; 22(4):453-464. PubMed ID: 32203417
[TBL] [Abstract][Full Text] [Related]
13. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
[TBL] [Abstract][Full Text] [Related]
14. The role of Hippo pathway signaling and A-kinase anchoring protein 13 in primordial follicle activation and inhibition.
Maher JY; Islam MS; Yin O; Brennan J; Gough E; Driggers P; Segars J
F S Sci; 2022 May; 3(2):118-129. PubMed ID: 35560009
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications.
Sun T; Chi JT
Genes Dis; 2021 May; 8(3):241-249. PubMed ID: 33997171
[TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma.
Papavassiliou KA; Sofianidi AA; Papavassiliou AG
J Cell Mol Med; 2024 Apr; 28(8):e18330. PubMed ID: 38606782
[TBL] [Abstract][Full Text] [Related]
17. Control of stem cell renewal and fate by YAP and TAZ.
Driskill JH; Pan D
Nat Rev Mol Cell Biol; 2023 Dec; 24(12):895-911. PubMed ID: 37626124
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Hippo Pathway Components by Gene Inactivation.
Plouffe SW; Meng Z; Lin KC; Lin B; Hong AW; Chun JV; Guan KL
Mol Cell; 2016 Dec; 64(5):993-1008. PubMed ID: 27912098
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of TAZ promotes cell proliferation, migration and epithelial-mesenchymal transition in ovarian cancer.
Chen G; Xie J; Huang P; Yang Z
Oncol Lett; 2016 Sep; 12(3):1821-1825. PubMed ID: 27588129
[TBL] [Abstract][Full Text] [Related]
20. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
